Subscribe

Dian Diagnostics Group Co.,Ltd. (300244.SZ)

CNY20.53 +0.67 (+3.37%)
CN SHZ Healthcare Medical - Diagnostics & Research
Address Building 2 310030
Hangzhou, CN
CEO Haibin Chen
Website dazd.cn
IPO 2011-07-19
ISIN CNE1000015N1

Explore sections of this company profile

Description

Dian Diagnostics Group Co.,Ltd. operates as a leading independent provider of medical diagnostic services within China. The company delivers comprehensive diagnostic solutions to a broad spectrum of healthcare organizations, including general and specialized hospitals, community health centers, township clinics, physical examination facilities, and disease prevention and control agencies. Supporting its extensive operations, Dian Diagnostics manages a global network of 40 advanced chain laboratories. Beyond its core diagnostic offerings, the company is also deeply involved in the research, development, and manufacturing of in vitro diagnostic reagents, along with associated equipment and consumables. Furthermore, it plays a crucial role in the medical supply chain, facilitating the provision of various products such as medical equipment, pharmaceuticals, clinical samples, biological products, finished blood products, live animals, chemical compounds, and diagnostic reagents. Dian Diagnostics also specializes in comprehensive cold chain logistics, which includes transportation, warehousing, product sales, and technical support services for temperature-sensitive medical goods. Founded in 2001, the company is headquartered in Hangzhou, China. It adopted its current name, Dian Diagnostics Group Co.,Ltd., in November 2017, having previously operated as Zhejiang DIAN Diagnostics Co., Ltd.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
CNY20.53 +0.67 (+3.37%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
30M
Beta
0.71
Float Shares
524.96M
Free Float %
84.0%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-0.79% -3.76% -8.69% -23.91% +11.21% +11.42% +23.67% -34.54% -57.34% -40.92% +291.57%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
20.53
DCF (Unlevered) 11.54 -43.8%
DCF (Levered) 28.60 +39.3%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 50% Bullish
Rating 2026-05 Change
Strong Buy 0 0
Buy 4 0
Hold 3 0
Sell 1 0
Strong Sell 0 0
Quality scores
Altman Z-Score
3.01
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
2 / 10
No MOAT
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Medical - Diagnostics & Research: +7.9%
    -17.2% Q1'26: -5.0% (vs Q1'25)
  • ✓
    EPS growth Medical - Diagnostics & Research: +30.8%
    +112.4% ★ Q1'26: +419.8% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%
    +11.3% Q1'26: -9.0% (vs Q1'25)
  • ✗
    EBIT margin Medical - Diagnostics & Research: +9.6%
    +4.1% Q1'26: +8.6% (vs Q1'25)
  • ✗
    ROIC Medical - Diagnostics & Research: +5.2%
    +3.2% Q1'26: +5.8% (vs Q1'25)
  • ✓
    Share dilution Medical - Diagnostics & Research: 0.0%
    -0.3% ★ Q1'26: +0.1% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×
    1.97× ★ Q1'26: 3.23× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.79) × ERP
WACC = 86% × Ke + 14% × Kd (9.4%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 11.54 Current price: 20.53
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
6 Rev. Ana.
3 EPS Ana. 		Dec 2027
7 Rev. Ana.
5 EPS Ana. 		Dec 2028
5 Rev. Ana.
4 EPS Ana.
Revenue
1.86B
est: 1.86B (+0.0%)
3.82B
est: 3.38B (+13.2%)
5.00B
est: 5.17B (-3.1%)
6.97B
est: 6.70B (+4.0%)
8.45B
est: 8.59B (-1.6%)
10.65B
est: 10.81B (-1.5%)
13.08B
est: 12.87B (+1.6%)
20.28B
est: 19.27B (+5.3%)
13.41B
est: 12.78B (+4.9%)
12.20B
est: 12.27B (-0.6%)
10.10B
est: 10.48B (-3.7%)
9.92B
9.51B – 10.50B
-5.4% YoY
10.33B
9.28B – 12.04B
+4.1% YoY
11.31B
11.19B – 11.44B
+9.5% YoY
EBITDA
229.68M
est: 293.46M (-21.7%)
471.99M
est: 533.45M (-11.5%)
655.61M
est: 815.93M (-19.6%)
1.07B
est: 1.06B (+1.2%)
1.26B
est: 1.36B (-7.1%)
2.20B
est: 1.71B (+28.6%)
2.47B
est: 2.03B (+21.4%)
4.25B
est: 3.04B (+39.6%)
1.47B
est: 1.71B (-14.4%)
928.27M
est: 1.64B (-43.6%)
874.07M
est: 1.41B (-37.8%)
1.33B
1.28B – 1.41B
-5.4% YoY
1.38B
1.24B – 1.61B
+4.1% YoY
1.52B
1.50B – 1.53B
+9.5% YoY
EBIT
191.54M
est: 238.52M (-19.7%)
411.08M
est: 433.58M (-5.2%)
538.77M
est: 663.17M (-18.8%)
892.77M
est: 859.87M (+3.8%)
1.01B
est: 1.10B (-8.2%)
1.90B
est: 1.39B (+37.1%)
2.13B
est: 1.65B (+28.7%)
3.66B
est: 2.47B (+47.8%)
1.01B
est: 1.29B (-21.5%)
546.34M
est: 1.24B (-55.9%)
417.65M
est: 1.06B (-60.5%)
1.00B
960.20M – 1.06B
-5.4% YoY
1.04B
936.72M – 1.21B
+4.1% YoY
1.14B
1.13B – 1.15B
+9.5% YoY
Net Income
174.79M
est: 209.29M (-16.5%)
262.76M
est: 270.98M (-3.0%)
349.59M
est: 389.58M (-10.3%)
388.61M
est: 413.61M (-6.0%)
347.28M
est: 408.87M (-15.1%)
802.93M
est: 857.79M (-6.4%)
1.16B
est: 1.26B (-7.8%)
1.43B
est: 1.41B (+2.0%)
307.46M
est: -74.09M (+515.0%)
-357.28M
est: -163.10M (-119.0%)
44.05M
est: 92.53M (-52.4%)
381.44M
355.12M – 449.21M
+312.2% YoY
499.70M
324.30M – 599.26M
+31.0% YoY
571.20M
476.84M – 601.24M
+14.3% YoY
SGA
411.68M
est: 292.69M (+40.7%)
739.08M
est: 532.05M (+38.9%)
916.36M
est: 813.80M (+12.6%)
1.20B
est: 1.06B (+14.0%)
1.36B
est: 1.35B (+0.3%)
1.65B
est: 1.70B (-3.0%)
2.21B
est: 2.03B (+9.0%)
2.75B
est: 3.04B (-9.2%)
2.22B
est: 1.78B (+24.5%)
1.98B
est: 1.71B (+15.7%)
649.53M
est: 1.46B (-55.6%)
1.38B
1.33B – 1.46B
-5.4% YoY
1.44B
1.29B – 1.68B
+4.1% YoY
1.58B
1.56B – 1.59B
+9.5% YoY
EPS
0.36
est: 0.34 (+5.4%)
0.48
est: 0.44 (+8.5%)
0.64
est: 0.64 (+0.6%)
0.71
est: 0.68 (+5.1%)
0.56
est: 0.67 (-16.1%)
1.29
est: 1.40 (-7.9%)
1.87
est: 2.06 (-9.2%)
2.30
est: 2.30 (+0.2%)
0.49
est: -0.12 (+512.0%)
-0.58
est: -0.26 (-123.1%)
0.07
est: 0.15 (-51.1%)
0.64
0.58 – 0.74
+334.6% YoY
0.76
0.53 – 0.98
+17.9% YoY
0.85
0.78 – 0.98
+12.8% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 B 3/5 4/5 3/5 4/5 2/5 1/5 3/5
2026-05-28 B 3/5 4/5 3/5 4/5 2/5 1/5 3/5
2026-05-27 B 3/5 4/5 3/5 4/5 2/5 1/5 3/5
2026-05-26 B 3/5 4/5 3/5 4/5 2/5 1/5 3/5
2026-05-25 B 3/5 4/5 3/5 4/5 2/5 1/5 3/5
2026-05-22 B 3/5 4/5 3/5 4/5 2/5 1/5 3/5
2026-05-21 B 3/5 4/5 3/5 4/5 2/5 1/5 3/5
2026-05-20 B 3/5 4/5 3/5 4/5 2/5 1/5 3/5
2026-05-19 B 3/5 4/5 3/5 4/5 2/5 1/5 3/5
2026-05-18 B 3/5 4/5 3/5 4/5 2/5 1/5 3/5
2026-05-15 B 3/5 4/5 3/5 4/5 2/5 1/5 3/5
2026-05-14 B 3/5 4/5 3/5 4/5 2/5 1/5 3/5
2026-05-13 B 3/5 4/5 3/5 4/5 2/5 1/5 3/5
2026-05-12 B 3/5 4/5 3/5 4/5 2/5 1/5 3/5
2026-05-11 B 3/5 4/5 3/5 3/5 2/5 1/5 3/5
2026-05-08 B 3/5 4/5 2/5 3/5 2/5 1/5 4/5
2026-05-07 B 3/5 4/5 2/5 3/5 2/5 1/5 4/5
2026-05-06 B 3/5 4/5 2/5 3/5 2/5 1/5 4/5
2026-04-30 B 3/5 4/5 2/5 4/5 1/5 1/5 4/5
2026-04-29 B- 3/5 4/5 2/5 4/5 1/5 1/5 3/5
2026-04-28 B- 3/5 4/5 2/5 4/5 1/5 1/5 3/5
2026-04-27 B 3/5 4/5 2/5 4/5 2/5 1/5 4/5
2026-04-24 B 3/5 4/5 2/5 4/5 1/5 1/5 4/5
2026-04-23 C+ 2/5 4/5 2/5 4/5 1/5 1/5 1/5
2026-04-22 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-04-21 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-04-20 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-04-17 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-04-16 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
1.59B
OE per share TTM
2.60
Owner's Yield
14.71%
Maintenance CapEx ratio
82.45%
Maint CapEx / Avg PPE
12.3%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 26 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 Dimensional - Emerging Markets Value ETF DFEV 0.01% 150.5K 0.46%
2 Franklin FTSE China UCITS ETF FLXC.L 0.01% 92.3K 0.19%
3 Dimensional - Emerging Markets Core Equity 2 ETF DFEM 0.00% 283.6K 0.39%
4 Dimensional Emerging Markets Sustainability Core 1 ETF DFSE 0.00% 13.1K 0.44%
5 Schwab Emerging Markets Equity ETF SCHE 0.00% 208.3K 0.06%
6 Dimensional - Emerging Core Equity Market ETF DFAE 0.00% 123.6K 0.29%
7 Dimensional World ex U.S. Core Equity 2 ETF DFAX 0.00% 109.9K 0.28%
8 Vanguard FTSE Emerging Markets Shares ETF VGE.AX 0.00% 12.6K 0.48%
9 Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO 0.00% 28.5K 0.26%
10 Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L 0.00% 51.5K 0.17%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
47.6K
Shares Outstanding
624.98M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Dekang Zhao Deputy GM, Head of Accounting Agency, Financial Manager & Director — male
Haibin Chen GM & Chairman of the Board — male
Hanhua Hong Deputy General Manager & Director — male
Jun Tao Deputy GM & Secretary of the Board — female
Sanhui Guo Deputy General Manager & Director — male
Weiyan Wu Deputy General Manager — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Diagnostics & Research